Company profile for Cereno Scientific

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Cereno Scientific is a clinical-stage biotech company developing better treatments for common and rare cardiovascular diseases. Cereno Scientific is a clinical-stage biotech company within common and rare cardiovascular disease. The experienced team at Cereno is dedicated to improve the health of patients with conditions that have high unmet needs, such as conditions with thrombosis, fibrosis, high pressure and inflammation. T...
Cereno Scientific is a clinical-stage biotech company developing better treatments for common and rare cardiovascular diseases. Cereno Scientific is a clinical-stage biotech company within common and rare cardiovascular disease. The experienced team at Cereno is dedicated to improve the health of patients with conditions that have high unmet needs, such as conditions with thrombosis, fibrosis, high pressure and inflammation. The project portfolio comprises a Phase II program and two preclinical programs.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Sweden
Address
Address
BioVentureHub Pepparedsleden 1 431 83 Mölndal, Sverige
Telephone
Telephone
556890–4071
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/cereno-scientific-to-attend-jpm-week-and-biotech-showcase-in-san-francisco-us-on-january-12-18-2026-302639988.html

PR NEWSWIRE BIO
12 Dec 2025

https://www.prnewswire.com/news-releases/cereno-scientific-submits-phase-iib-trial-protocol-for-cs1-in-pulmonary-arterial-hypertension-pah-to-the-us-fda-302609911.html

PR NEWSWIRE
10 Nov 2025
Cereno's HDAC inhibitor reduces risks from PAH in phase 2 trial
Cereno's HDAC inhibitor reduces risks from PAH in phase 2 trial

30 Sep 2024

// James Waldron FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/cerenos-hdac-inhibitor-reduces-risks-pulmonary-arterial-hypertension-phase-2-trial

James Waldron FIERCE BIOTECH
30 Sep 2024

https://news.cision.com/cereno-scientific/r/cereno-scientific-obtains-first-patent-in-europe-for-drug-candidate-cs585,c3635866

CISION
23 Sep 2022

https://news.cision.com/cereno-scientific/r/cereno-scientific-broadens-patent-protection-for-drug-candidate-cs585-and-strengthens-its-future-com,c3628527

CISION
09 Sep 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty